Meeting Banner
Abstract #4812

Glioblastoma Characterization with Hyperpolarized [1-13C]Pyruvate MRSI, DWI and 18F-FDG PET

Geoffrey J. Topping1, Roland E. Kälin2, Linzhi Cai2, Rainer Glaß2, and Franz Schilling1
1Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany, 2Neurosurgical Research, University Clinics Munich, Ludwig Maximilian University, Munich, Germany

Multimodal imaging has the potential for non-invasive assessment of imaging biomarkers that guide and monitor treatment of glioblastoma tumours. In this work, an imaging protocol for characterization of implanted patient-derived and murine glioblastoma tumours (GBM2, GBM14, and U87) was established using T2-weighted MRI, DWI, hyperpolarized 13C-pyruvate-lactate CSI, and 18F-FDG PET. Tumours were visible in T2-weighted MRI as high-signal regions with poorly defined borders. Compared with shams and non-tumour brain, all tumour lines had elevated ADC, 18F-FDG Ki, and lactate-to-pyruvate ratio. GBM2 had particularly high and variable lactate-to-pyruvate ratio, despite relatively low variability in ADC.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here